# CONTENTS

NOTE TO THE READER ........................................................................................................... 1

LIST OF PARTICIPANTS ........................................................................................................... 3

PREAMBLE ................................................................................................................................ 9
   Background ............................................................................................................................. 9
   Objective and Scope ............................................................................................................ 9
   Selection of Topics for Monographs .................................................................................... 10
   Data for Monographs .......................................................................................................... 11
   The Working Group ............................................................................................................ 11
   Working Procedures ........................................................................................................... 11
   Exposure Data ..................................................................................................................... 12
   Studies of Cancer in Humans ............................................................................................. 14
   Studies of Cancer in Experimental Animals ....................................................................... 17
   Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .................. 20
   Summary of Data Reported ............................................................................................... 22
   Evaluation ............................................................................................................................ 23
   References ............................................................................................................................ 27

GENERAL REMARKS .............................................................................................................. 33

THE MONOGRAPHS ................................................................................................................. 47
   Drugs ..................................................................................................................................... 49
      Anti-thyroid drugs ............................................................................................................ 51
         Methimazole ................................................................................................................. 53
         Methylthiouracil ............................................................................................................ 75
         Propylthiouracil ............................................................................................................ 91
         Thiouracil ..................................................................................................................... 127
      Sedatives ......................................................................................................................... 143
         Doxylamine succinate ................................................................................................. 145
         Phenobarbital and its sodium salt ................................................................................ 161
      Antifungal agent: Griseofulvin ....................................................................................... 289
      Diuretic: Spironolactone ............................................................................................... 317
<table>
<thead>
<tr>
<th>Category</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibacterial agents</td>
<td>339</td>
</tr>
<tr>
<td>Sulfamethazine and its sodium salt</td>
<td>341</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>361</td>
</tr>
<tr>
<td>Pesticides</td>
<td>379</td>
</tr>
<tr>
<td>Amitrole</td>
<td>381</td>
</tr>
<tr>
<td>Chlordane and heptachlor</td>
<td>411</td>
</tr>
<tr>
<td>Hexachlorobenzene</td>
<td>493</td>
</tr>
<tr>
<td>Toxaphene</td>
<td>569</td>
</tr>
<tr>
<td>Food and cosmetics agent: Kojic acid</td>
<td>605</td>
</tr>
<tr>
<td>Hair dye: 2,4-Diaminoanisole and its salts</td>
<td>619</td>
</tr>
<tr>
<td>Industrial chemicals</td>
<td>647</td>
</tr>
<tr>
<td>$N,N'$-Diethylthiourea</td>
<td>649</td>
</tr>
<tr>
<td>Ethylenethiourea</td>
<td>659</td>
</tr>
<tr>
<td>Thiourea</td>
<td>703</td>
</tr>
</tbody>
</table>

SUMMARY OF FINAL EVALUATIONS .........................................................727

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–78 ..................................729

CUMULATIVE INDEX TO THE MONOGRAPHS SERIES .........................731
The term 'carcinogenic risk' in the IARC Monographs series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.